Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.21 EUR | -5.47% | -12.45% | -11.68% |
04-10 | Transgene: presents vaccine results at AACR | CF |
03-28 | Transgene CFO Steps Down; Successor Assumes Office | MT |
Sales 2023 | 7.9M 8.45M 676M | Sales 2024 * | 39.8M 42.55M 3.41B | Capitalization | 122M 130M 10.42B |
---|---|---|---|---|---|
Net income 2023 | -22M -23.52M -1.88B | Net income 2024 * | -13M -13.9M -1.11B | EV / Sales 2023 | 17.6 x |
Net Debt 2023 | 1.63M 1.74M 139M | Net Debt 2024 * | 16.4M 17.54M 1.4B | EV / Sales 2024 * | 3.47 x |
P/E ratio 2023 |
-6.23
x | P/E ratio 2024 * |
-8.64
x | Employees | 143 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 34.45% |
Latest transcript on Transgene
1 day | -5.47% | ||
1 week | -12.45% | ||
Current month | +6.14% | ||
1 month | +8.81% | ||
3 months | -7.35% | ||
6 months | -13.32% | ||
Current year | -11.68% |
Managers | Title | Age | Since |
---|---|---|---|
Alessandro Riva
CEO | Chief Executive Officer | 63 | 30/03/22 |
Lucie Larguier
DFI | Director of Finance/CFO | - | 31/03/16 |
Maud Brandely
CTO | Chief Tech/Sci/R&D Officer | 70 | 16/03/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 74 | 18/06/13 | |
Alain Mérieux
BRD | Director/Board Member | 85 | 31/12/90 |
Director/Board Member | 63 | 06/12/04 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 1.21 | -5.47% | 74,243 |
25/04/24 | 1.28 | -4.90% | 50,816 |
24/04/24 | 1.346 | +1.82% | 12,204 |
23/04/24 | 1.322 | -0.60% | 15,316 |
22/04/24 | 1.33 | -3.76% | 43,299 |
Real-time Euronext Paris, April 26, 2024 at 04:35 pm
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-11.68% | 130M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- TNG Stock